Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Attenuation of GAP3KO Malaria Vaccine
NCT02313376Phase 1Completed
- Sponsor
- Seattle Children's
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Gene Editing, Gene Silencing, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GAP3KO in malaria, sponsored by Seattle Children's. Primary endpoint: Safety assessed by frequency of AEs, SAEs, and patent parasitemia via peripheral blood smear at 28 days. Started Dec 2014; status: completed.
02
Drugs
GAP3KO
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02313376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313376.